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Abstract
Cervical cancer is known to metastasize primarily by the lymphatic system. Dissemination through lymphatic ves-
sels represents an early step in regional tumor progression, and the presence of lymphatic metastasis is associ-
ated with a poor prognosis. In patients who have undergone a radical hysterectomy, lymphovascular space
invasion (LVSI), assessed on hematoxylin and eosin–stained slides, is a major factor for adjuvant therapy in patients
with cervical cancer. With the advent of a lymphatic endothelial cell–specific marker, such as D2-40, it is now
possible to distinguish between blood and lymphatic space invasion (LSI). In this study, the utility of D2-40 was
assessed for the detection of lymphatic vessel density (LVD) and identification of LSI. The expressions of vascular
endothelial growth factor receptor-3 (VEGFR-3), VEGF-C, tyrosine receptor kinase-2, and angiopoietin-1 were as-
sessed by immunohistochemical methods on 50 patients with squamous cell carcinoma of the cervix. Clinicopath-
ologic characteristics, including pelvic lymph node metastasis, were correlated with the above histochemical
findings. We found that lymphangiogenesis, measured by an increase in peritumoral LVD, was significantly asso-
ciated with positive lymph node status (P < .005). VEGFR-3 expression was significantly associated with LVD
(P < .05). D2-40 staining verified LSI (P = .03) and surpassed that of hematoxylin and eosin–identified LVSI (P =
.54). In conclusion, lymphangiogenic markers, specifically LVD quantified by D2-40 and VEGFR-3, are independently
associated with LSI and lymph node metastasis in patients with early squamous cell carcinoma of the cervix treated
with radical hysterectomy and pelvic lymphadenectomy.
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Introduction
Lymph node metastasis is a major cause of death from cervical car-
cinoma. Lymphatic vessels provide natural drainage, and they are the
preferential routes for metastatic spread of many cancers, including
most carcinomas that arise from vulva, vagina, and cervix [1]. Dis-
semination through lymphatics represents an early step in regional
tumor progression, and the presence of lymphatic metastasis is asso-
ciated with more aggressive tumors, with a poor prognosis. The clinical
and pathological nodal status guides important treatment decisions
about adjuvant treatment options when surgery is performed.
It was previously thought that lymphatic metastases involved the
constant migration of malignant cells along preexisting lymphatic
channels originating near the tumor, that is, the Halstead hypothesis
[2]. Dissemination of cancer cells is now considered to be more epi-
sodic, occurring through emboli, rather than the steady march of cells,
and may be through newly formed lymphatic vessels [3].
Address all correspondence to: Shaleen K. Botting, MS, Baylor College of Medicine, One
Baylor Plaza, MS:BCM610, Houston, TX 77030. E-mail: botting@bcm.tmc.edu
1Current address: Department of Obstetrics & Gynecology, Division of Gynecologic
Oncology, Baylor College of Medicine, Houston, TX.
Received 29 September 2009; Revised 14 December 2009; Accepted 15 December 2009
Copyright © 2010 Neoplasia Press, Inc. All rights reserved 1944-7124/10/$25.00
DOI 10.1593/tlo.09292
www.transonc.com
Trans la t iona l Onco logy Volume 3 Number 3 June 2010 pp. 170–175 170
Lymphatic vessel density (LVD) is an emerging prognostic factor
associated with regional lymph node metastases, distant metastasis,
and poor overall survival [4,5]. Although peritumoral lymphatic ves-
sels contribute to tumor metastasis, there is the question as to whether
intratumoral lymphatics have a role in tumor metastasis [6]. Thus, the
location of tumor lymphatics may be an important factor in the meta-
static spread of cancer cells.
The precise mechanisms whereby the newly formed lymphatics
promote cancer progression are not well understood. However,
several mechanisms have been postulated. A change of lymphatic
function and an increase in lymphatic density alter the tumor micro-
environment and its propensity for metastasis. Furthermore, cyto-
kines direct from the lymphatic endothelial cells may facilitate tumor
spread by promoting tumor cell migration toward, and invasion into,
the vessel [7].
Vascular endothelial growth factor C (VEGF-C), a novel VEGF
member, has been found to induce lymphangiogenesis through acti-
vation of the tyrosine kinase VEGF receptor 3 (VEGFR-3). VEGFR-
3 is expressed predominantly on the surface of adult lymphatic
endothelial cells and is therefore considered a major regulator of
lymphangiogenesis [2,8]. The monoclonal antibody D2-40 [9] was
recently reported to be selective for lymphatic endothelium, and it
has identified lymphatic invasion in many malignant tumors [10].
There have been few studies to date on lymphangiogenesis due to the
lack of these specific lymphatic endothelial markers and lymphatic-
specific growth factors.
Lymphovascular space invasion (LVSI), defined as the identifica-
tion of “any tumor inside endothelial-lined spaces in the primary
tumor site by microscopy” [11], has been found to significantly in-
crease the risk of lymph node involvement [12,13]. However, this is a
combined parameter unable to distinguish invasion of lymphatic and
blood capillaries at the primary tumor site. Despite its strong prog-
nostic relevance, there has been no standardization in the measure-
ment of true lymphatic space invasion (LSI) or LVD.
Methodical problems arise first in the identification and visual-
ization of the lymphatic vessel wall after hematoxylin and eosin
(H&E) staining using conventional light microscopy [14,15]. Diffi-
culty also arises with the ability to discern “viable” tumor emboli
within lymphatic lumens [16] and to identify retraction artifact,
due to fixation, versus true lymphatic vessel space [17]. Previous stud-
ies have assessed peritumoral LVD by measuring the area with high-
est LVD, the so-called hot spot, and have not evaluated the entire
stroma’s vessel density; this generates selection bias and does not ac-
count for the entire tumor microenvironment [7,18]. The accurate
assessment of LSI and LVD requires specific immunohistochemical
markers for lymphatic vessels based on a standard protocol for micro-
vessel count.
The mechanism by which newly formed lymphatics promote can-
cer metastasis is not well understood. Therefore, the aims of the
present study were to apply the novel antibody D2-40 to squamous
cell cervical cancers and evaluate its sensitivity for LVSI, to develop a
mathematical assessment to quantify LVD, to compare LSI as de-
tected by D2-40 immunostaining with that of conventional LVSI
as detected by H&E staining, to investigate whether LVD intratumo-
rally or peritumorally is a reliable risk factor for lymph node metas-
tasis and cancer recurrence, and, finally, to investigate whether
VEGF-C, VEGFR-3, angiopoietin-1 (ANG-1), and tyrosine receptor
kinase-2 (TIE-2) are independent prognostic markers for cervical
cancer metastasis.
Materials and Methods
Cervical Tissue Specimens and Patient Characteristics
We extracted 40 cases of invasive squamous cell carcinoma of the
cervix from the Department of Surgical Pathology database at the Uni-
versity of Texas Medical Branch, Galveston, Texas, between the years
2007 and 2008. All patients had undergone radical hysterectomy with
lymph node dissection. H&E–stained slides were reviewed, and the
diagnoses were verified. Tissue samples and patient information were
collected with full institutional review board approval.
Cases were evaluated for patient’s age, clinical stage, clinical tumor
size, and treatment. Staging was defined according to the clinical
staging system of Federation Internationale des Gynaecologistes et
Obstetristes [19].
Histopathologic Examination
Tissues from the specimens were initially fixed in 10% buffered
formalin, paraffin-embedded, processed, and stained with H&E,
by the Surgical Pathology Department as a part of the routine intake
procedure. H&E slides of all cases were reviewed to confirm the di-
agnosis and the histopathologic characteristics including histologic
type, pathological tumor size, depth of invasion, the presence of
lymphatic and LVSI, grade, pelvic, and para-aortic lymph node me-
tastasis. Four tumor-containing paraffin-embedded tissue blocks,
identified on the histologic H&E review, were then selected from
each patient for the purpose of this article’s immunohistochemical
studies. The clinicopathological features of the tumors are summarized
in Table 1.
Immunohistochemical Analysis
Serial 5-μm sections were cut from formalin-fixed, paraffin-
embedded tissue and were mounted on precoated slides for immuno-
histochemical detection of D2-40, VEGF-C, VEGFR-3, ANG-1, and
TIE-2. Four goat polyclonal antibodies and one mouse monoclonal
antibody were used for this study. The goat polyclonal antibodies,
anti–VEGF-C (AF752), anti–VEGF receptor-3 (AF349), anti–ANG-1
(AF923), and anti–TIE-2 (AF313) were purchased from R&D Systems
(Minneapolis, MN) and used at the concentrations of 7.5, 2.0, 5.0, and
7.0 μg/ml, respectively. Mouse monoclonal antibody D2-40, which
reacts with an O-linked sialoglycoprotein found on lymphatic endothe-
lium, was purchased from Signet Laboratories (Dedham, MA) and was
used at a dilution of 1:200.
Table 1. Association between Clinicopathological Variables and Lymphatic Metastases in Cervical
Cancer (n = 35).
Parameters No. Specimens P
Total 35
Stage .704
1A/B 31
2A 4
Age, years .2205
Mean 42
Depth of invasion .043
<2 mm free 12
>2 mm free 23
Tumor size .244
>4 cm 14
<4 cm 21
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Immunohistochemical assays were performed using the avidin-
biotin-peroxidase complex (ABC) assay for all five primary antibodies.
The 5-μm-thick sections were deparaffinized in xylene and rehydrated
in graded ethanol. Endogenous peroxidase activity within the tissue was
quenched by treating with 3% hydrogen peroxide (H2O2) in methanol
for 20minutes. Antigen retrieval was achieved by placing the sections in
preheated (95-100°C) 0.01M citrate buffer, pH 6.0, with 0.1% Tween
20 for 20 minutes. Nonspecific binding sites were blocked with rabbit
normal serum (Vectastain ABC kit; Vector Laboratories, Burlingame,
CA) in phosphate-buffered saline for 20 minutes at room temperature.
Primary antibodies for VEGF-C, VEGFR-3, and TIE-2 were used at
the concentrations mentioned above, and the slides were incubated
overnight at 4°C. Slides for ANG-1 were incubated 2 hours at room
temperature. Subsequent incubation with the biotinylated secondary
antibody, antigoat immunoglobulin G (Vectastain ABC kit; Vector
Laboratories) was then performed for 30 minutes. The slides were then
incubated with streptavidin-biotin-peroxidase complex (ABC) for
30 minutes. Finally, the peroxidase reactivity was visualized with
3,3′-diaminobenzidine (DAB; Vector Laboratories) according to the
manufacturer’s instructions. The sections were counterstained with Gill
2× hematoxylin (Fisher cat. no. 245-654) and mounted. Negative con-
trols were performed by omitting the primary antibodies. The positive
control was a single patient with squamous cell cervical cancer whose
formalin-fixed paraffin-embedded sections were stained with for each
batch of antibody.
For the detection of lymphatic channel endothelium, the same immu-
nohistochemical procedures were followed except the use of different
blocking serum, primary antibody, and secondary antibody. The tissue
sections were blocked with normal horse serum (Vector Laboratories)
for 20 minutes at room temperature and then incubated with primary
D2-40 antibody (mouse monoclonal, 1:200 dilution; Signet Laboratories)
for 1 hour at room temperature. Biotinylated secondary antibody, anti-
mouse immunoglobulin G (Vectastain ABC kit; Vector Laboratories),
was used.
Evaluation of Immunohistochemical Staining
The expressions of VEGF-C, VEGFR-3, ANG-1, and TIE-2 were
scored by the staining intensity of the tumor cells. The intensity score
was defined as follows: 1+, faint or equivocal immunoreaction; 2+,
weak immunoreaction; 3+, moderate; and 4+, strong immunoreaction.
Demarcation of Peritumoral Region and
Lymphatic Vessel Quantification
Whole-slide imaging of the entire D2-40–stained histopathologic
section, as originally mounted on glass microscope slides, was ob-
tained using the Aperio automated scanning robot (T2; Aperio Tech-
nologies, Vista, CA). This has a 20× microscope objective at a spatial
sampling period of 0.47 μm per pixel. The images were subsequently
viewed using the ImageScope software (Aperio Technologies).
For the purpose of this study, we strictly defined two peritumoral
regions of interest. The first peritumoral region was defined as the
area spanning 100 μm from the obvious tumor margin to 1 mm.
The second peritumoral region was defined as the next 1 to 2 mm
from the original tumor margin (Figure 1). LVD was defined as the
number of D2-40–positive spaces per square millimeter for a speci-
fied region.
This strict assessment of LVD was performed using the Aperio
slide-scanning software. All D2-40–immunoreactive spaces were
counted within the two peritumoral regions of the full slide image
and, subsequently, divided by the total area of the defined region,
yielding LVD in spaces per square millimeter. Groups of immunore-
active endothelial cells, with or without patent lumens, were counted
as a lymphatic space. LSI, detected by immunohistochemical stain-
ing, was considered positive if a tumor cell or cluster of tumor cells
was clearly visible inside the D2-40–immunopositive space.
Statistical Analysis
All statistical calculations were carried out using SAS Software,
Version (9.2) of the SAS System for Windows (Cary, NC). The
Cochran-Mantel-Haenszel test was used to compare and determine
whether there was a significant difference in immunohistochemical
expression within the VEGF-C, VEGFR-3, ANG-1, and TIE-2 groups
and to determine whether there was a correlation between any of the
above variables with clinicopathological parameters. Level of statistical
significance was set at P ≤ 0.05.
Results
Reclassification of Patients by D2-40 Immunohistochemistry
The D2-40 antibody, known to selectively stain lymphatic endo-
thelial cells, identified lymphatic channels within tumor and in the
peritumoral stroma. Endothelial cells lined spaces devoid of blood
cells (indicative of lymphatic spaces) stained strongly, whereas obvi-
ous blood vessels showed no immunolabeling with D2-40 (Figure 2).
Myoepithelial cells were also immunoreactive to D2-40, but differ-
entiation of myoepithelium from lymphatic epithelium was uncom-
plicated based on size, location, and organization. One patient was
removed from the study owing to diagnosis of lymphoepithelioma-
like carcinoma. In addition, four patients were removed from the
study owing to insufficient tissue to complete all immunohistochem-
ical analysis.
D2-40–confirmed LSI was compared with the occurrence of LVSI
identified on the H&E slide by pathology at the time of surgery and
Figure 1. Designation of peritumoral regions. Aperio Scan Scope
(Aperio Technologies) image of D2-40–stained formalin-fixed,
paraffin-embedded squamous cell carcinomaof the cervix. Green line
directly adjacent to tumor mass designates tumor boundary. Peri-
tumoral region 1 was set as the region spanning 1 mm from the
tumoral border, designated by the yellow line. Peritumoral region 2
spanned 1 mm from the boarder of region 1, designated by the
orange line. s indicates stroma; t, tumor. Original magnification, ×2;
scale bar, 1 mm.
172 Lymphangiogenesis in Cervical Cancer Botting et al. Translational Oncology Vol. 3, No. 3, 2010
verified independently by the study pathologist. LSI was found pre-
dominately in the stroma directly adjacent to the tumor, rarely ex-
tending past 1 mm from the tumor, regardless of tumor size.
Using the Cochran-Mantel-Haenszel test to compare the two
groups based on the binary response, LSI or LVSI-positive or
LVSI-negative, no association or no pattern of association was found
between LSI and LVSI status. LSI was found to be independently
statistically associated with nodal status, independent of LVSI status
(P = .0009), whereas the converse was not true (Table 2).
Correlation of LVD with Clinicopathological Prognostic
Factors in Cervical Cancer
D2-40 verified an increased presence of lymphatic vessels in stroma
directly adjacent to tumor. Lymphatic vessels within tumor were rare
and, if found, were collapsed. One tumor was found to have an ex-
tremely large number of patent intratumoral lymphatics: after further
histologic review, the condition of this patient was diagnosed as lympho-
epithelioma-like carcinoma. This patient’s sample was then removed
from the study set.
We found the LVD of peritumoral region 1, directly adjacent to
the tumor, to be 1.25-fold (P < .05, analysis of variance [ANOVA];
Figure 3A ) that of peritumoral region 2. Peritumoral LVD showed
no correlation with patient age, tumor size, or depth of invasion.
LVD in peritumoral region 1 (LVD1) showed a greater correlation with
lymph node metastasis (P = .0005, ANOVA; Figure 3C ) when com-
pared with peritumoral region 2 (LVD2; P = .015, ANOVA; Figure 3B)
and have a positive correlation with LSI (P = .015, ANOVA).
The median number of positive lymph nodes was 2 (range, 1-10).
Lymph node metastasis was present in 14 cases (40%).
Cochran-Mantel-Haenszel test performed showed an increase in
LSI or LVD1 to be statistically significant at predicting lymph node
positivity at the time of surgery (P < .05; Table 2). In addition, LSI
was found to have superior odds ratio estimate compared with LVD1
of 15.91 (95% confidence interval [CI], 1.29-195.1) and 1.78 (95%
CI, 1.01-3.14), respectively.
Correlation of Immunohistochemical Markers with Lymphatic
Space Density
Multiple regression analysis of the predictors of LVD, VEGFR-3,
VEGF-C, ANG-1, and TIE-2 was performed. Significant positive
correlation was found between VEGFR-3 (P = .006) and ANG-1
levels within the tumors with peritumoral LVD (P = .0298). Staining
of both VEGFR-3 and ANG-1 was found to be homogenous within
the tumor and present in advanced dysplastic epithelium (Figure 4).
No statistical correlation was found between VEGF-C or TIE-2
and LVD.
Discussion
Combined parameters of lymphatic invasion, margin status, tumor
size, depth of invasion, parametrial involvement, and stage all guide
physicians in the recommendation of adjuvant treatment. Lymph
node positivity has repeatedly been shown to have an ominous sur-
vival impact, with a 67% 5-year survival in stage IB cancer patients
[20] to 91% in node-negative patients [21]. Adjuvant treatment of
this cancer is, as a standard, a combination of chemotherapy and
radiation therapy [22,23]. Identification of LSI has been shown to
predict nodal metastasis, and the use of this novel antibody stan-
dardizes the histologic assessment of an important prognostic factor
in squamous cell cervical cancer improving its predictive ability.
In early cervical cancer, lymphatic involvement has been one of
the more difficult parameters to quantify owing to fixation artifact,
tumor sampling discrepancy, and proper identification of lymphatic
channels. We have used the antibody D2-40 to improve the identi-
fication of lymphatic vessels in radical hysterectomy specimens, aid-
ing in the verification of LSI. We have found that the identification
of D2-40–verified LSI is far superior than relying on H&E staining
for the prediction of nodal metastasis.
D2-40 lymphatic vessels were almost exclusively found at the
interface between the stroma and tumor and not within the tumor,
a finding in good accordance with published studies [24–26]. One
Figure 2. Utility of D2-40 immunohistochemical staining. (A) Typical results of immunostaining with the D2-40 antibody, brown staining
selectively present in lymphatic endothelium. (B) Commonly seen retraction artifact mimicking LVSI. (C) D2-40–stained endothelial cells,
stained brown, verify the presence of true LSI of the cancer cells. Without the use of the lymph epithelial–specific immunohistochem-
istry staining, differentiation between panels A and B would prove difficult and subjective. Original magnification, ×20.
Table 2. Correlation of LSI and Lymph Node Metastasis Independently Controlling for Either
LVSI (A) or LSI (B).
LSI− LSI+
LVSI+ LVSI− LVSI+ LVSI−
(A) LVSI by Lymph Node Status Controlling for LSI
Lymph node metastasis
pN+ primary tumors (n = 14) 0 1 8 5
pN0 primary tumors (n = 21) 5 9 4 3
P (Cochran-Mantel-Haenszel) .9
(B) LSI by Lymph Node Status Controlling for LVSI
Lymph node metastasis
pN+ primary tumors (n = 14) 5 1 8 0
pN0 primary tumors (n = 21) 3 9 4 5
P (Cochran-Mantel-Haenszel) .0009
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hypothesis for the lack of functional intratumoral lymphatic vessels is
owing to the collapse by the physical stress exerted by the growing
tumor [26]. Our studies revealed that cervical cancers with high
peritumoral lymph angiogenesis, measured with peritumoral LVD,
are significantly more often associated with nodal metastasis. The
significant association between LVD and LSI could simply be ex-
plained through classic probability, where lymphangiogenesis induces
increase of opportunities for the tumor cells to enter lymphatic ves-
sels. We found a significant correlation in both LSI and LVD with
regional nodal metastasis.
In our studies, we found that the LVD1 directly adjacent to the
tumor (within 1 mm) showed a greater correlation with lymph node
metastasis when compared with the second peritumoral region (LVD2),
suggestive of a paracrine lymphangiogenic mechanism involving the
malignant cells. Four known lymphangiogenic factors were studied in
the cervical epithelium for their correlation to LVD and nodal metas-
tasis. VEGFR-3 is expressed differentially by cervical epithelial cells.
Whereas VEGFR-3 was found in both malignant and nonmalignant
cells, expression of VEGFR-3 was negative or faint in normal non-
dysplastic cervical epithelium and unregulated in the highly dysplastic
epithelium as well as carcinoma. Although the role of epithelial expressed
VEGFR-3 in lymph angiogenesis remains to be established, VEGFR-3
expression in neoplasia may play an important role in facilitating
lymphatic dissemination of cervical cancer. Our study revealed a statisti-
cally significant correlation betweenVEGFR-3 expression fromneoplas-
tic cells and regional lymph node metastasis. This finding is consistent
Figure 3. Peritumoral LVD in cervical squamous cell carcinoma. (A) LVD in peritumoral region 1, when compared with region 2, was
found to be 1.25-fold higher. (B and C) Comparison of peritumoral LVD in region 2 (B) and region 1 (C) with the absence and presence of
lymph node metastasis. Lines indicate median VEGFR-3 immunostaining score values. *P < .05; ***P = .0005, ANOVA.
Figure 4. Immunohistochemical expression of VEGFR-3 in invasive cervical squamous cell carcinoma. VEGFR-3 immunopositivity was
found in the cytoplasm of the tumor cells. Expression is heterogeneous within the tumor yet variable between patients. VEGFR-3 ex-
pression was graded from 1+ (faint staining; A) to 4+ (intense staining; B). Intensity of staining was found to have a statistically sig-
nificant positive correlation with lymph node metastasis (P < .05, ANOVA). s indicates stroma; t, tumor. Original magnification, ×40.
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with findings in prostate cancer [27,28], both of which found VEGF-3
expression associated with more aggressive poorly differentiated tumors.
In conclusion, immunohistochemically confirmed peritumoral LSI
predicts regional lymph node metastasis with an odds ratio of 15.91,
significantly improving the utility of LSI to guide therapeutic deci-
sions. Correlation of peritumoral LVD with nodal metastasis suggests
a role for lymph angiogenesis in the metastatic phenotype and a tumor-
modulated paracrine lymphangiogenic mechanism. Finally, up*-
regulation of VEGFR-3 early in the carcinogenic process may indicate
a more aggressive phenotype with a higher propensity for early lym-
phatic dissemination.
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